Surfactant therapy for bronchiolitis in critically ill infants 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 79 participants
Moderate

Intervention not reported

Risk of VAP within 10 days of intubation in participants intubated for ≥ 24 hours · People who are mechanically ventilated

The intervention may leads to lower risk of VAP within 10 days of intubation in participants intubated… (low certainty).

1 finding from 1 review

Silver‐coated endotracheal tubes for prevention of ventilator‐associated pneumonia in critically ill patients 2015 · Cochrane Headline outcomes only
RR 0.51 [0.31, 0.82]
1 study · 1509 participants
Low

Low molecular weight heparin vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Defibrotide vs no treatment

All‐cause mortality at 100 days post‐transplant · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease

Summary of findings: Defibrotide showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 1.05 [0.56, 1.97]
1 study · 360 participants
Low

Glutamine vs placebo

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.3 [0.01, 6.84]
1 study · 34 participants
Very low

Ursodeoxycholic acid vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
RR 0.7 [0.5, 0.99]
4 studies · 612 participants
Low

Fresh frozen plasma vs no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Antithrombin III plus heparin vs heparin

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for prophylaxis of hepatic veno‐occlusive disease in people undergoing haematopoietic stem cell… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found